Immix Biopharma, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Immix announced interim Phase 2 results for NXC-201 (CAR-T therapy) in relapsed/refractory AL Amyloidosis across 45 patients: 89% complete response rate (40/45), with all 25 new patients either in CR or MRD-negative; 4 additional MRD-negative patients could push CR rate to 98% (44/45) if confirmed. No relapses, neurotoxicity, or enterocolitis observed. Final readout and BLA submission planned mid-2027.
Why this rating
Strong interim efficacy data materially de-risks lead program for $35.7M-cap biotech; upcoming BLA potential near-term catalyst, but binary regulatory outcome remains. Major catalyst for this size.
Tradability signal
NO TRADE
No trade: positive news with only +1.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.38% over 4 hrs, n=124). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $11.60 ▼ 0.85% | at our read · unknown $11.70 | +10 min · unknown $11.05 ▼ 5.51% | +30 min · unknown $10.62 ▼ 9.23% | +1 hr · unknown $10.20 ▼ 12.82% | +4 hrs · unknown $10.14 ▼ 13.33% |
The stock had already moved +0.86% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.